CD274 and non-small cell lung carcinoma: The widespread developments of immune checkpoint blockades (ICBs), notably antibodies targeting programmed cell death receptor-1/ligand-1 (PD-1/PD-L1), have greatly broadened the treatment options for solid tumours including NSCLC.